MALDI-TOF MS Identifies Oomycete Causing Pythiosis
|
By LabMedica International staff writers Posted on 12 Dec 2018 |

Image: The UltrafleXtreme MALDI-TOF/TOF mass spectrometer (Photo courtesy of Bruker Daltonics).
Pythiosis is an invasive, difficult-to-treat, life-threatening infectious disease caused by Pythium insidiosum, a member of the unique group of fungus-like microorganisms called oomycetes. The disease has been increasingly reported worldwide.
In the past decade, the matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) has emerged as a novel and powerful diagnostic tool for facilitating the clinical identification of many pathogenic microorganisms, including bacteria and fungi.
Scientists at the Mahidol University (Bangkok, Thailand) isolated a total of 13 strains of P. insidiosum, isolated from eight humans and five animals with pythiosis, from different geographic locations. All organisms were maintained on Sabouraud dextrose agar at 25 °C. Several small portions of a colony of each organism were transferred to a 50-mL flask containing 10 mL Sabouraud dextrose broth, and incubated at 37 °C for one week, before harvesting fungal material for protein extraction.
Protein was extracted from harvested organisms and was spotted onto a clean ground steel target plate in 40 replicates (for generating a MALDI-TOF MS database of P. insidiosum) or five replicates (for assessing the MALDI-TOF MS for identification of P. insidiosum), air dried at room temperature before being processed. After the matrix solution was air dried at room temperature, the sample was promptly analyzed, using a Bruker ultrafleXtreme mass spectrometer. Genomic DNA (gDNA) templates were extracted from the organisms and subjected to single nucleotide polymorphism-based multiplex polymerase chain reaction (PCR).
The team reported that the MALDI-TOF MS accurately identified all 13 P. insidiosum strains tested, at the species level. Mass spectra of P. insidiosum did not match any other microorganisms, including fungi (i.e., Aspergillus species, Fusarium species, and fungal species of the class Zygomycetes), which have similar microscopic morphologies with this oomycete. MALDI-TOF MS- and rDNA sequence-based biotyping methods consistently classified P. insidiosum into three groups: Clade-I (American strains), II (Asian and Australian strains), and III (mostly Thai strains).
The authors concluded that MALDI-TOF MS has been successfully used for identification and biotyping of P. insidiosum. The obtained mass spectral database allows clinical microbiology laboratories, well equipped with a MALDI-TOF mass spectrometer, to conveniently identify P. insidiosum, without requiring any pathogen-specific reagents (i.e., antigen, antibody or primers). The study was published in the December 2018 issue of the International Journal of Infectious Diseases.
Related Links:
Mahidol University
In the past decade, the matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) has emerged as a novel and powerful diagnostic tool for facilitating the clinical identification of many pathogenic microorganisms, including bacteria and fungi.
Scientists at the Mahidol University (Bangkok, Thailand) isolated a total of 13 strains of P. insidiosum, isolated from eight humans and five animals with pythiosis, from different geographic locations. All organisms were maintained on Sabouraud dextrose agar at 25 °C. Several small portions of a colony of each organism were transferred to a 50-mL flask containing 10 mL Sabouraud dextrose broth, and incubated at 37 °C for one week, before harvesting fungal material for protein extraction.
Protein was extracted from harvested organisms and was spotted onto a clean ground steel target plate in 40 replicates (for generating a MALDI-TOF MS database of P. insidiosum) or five replicates (for assessing the MALDI-TOF MS for identification of P. insidiosum), air dried at room temperature before being processed. After the matrix solution was air dried at room temperature, the sample was promptly analyzed, using a Bruker ultrafleXtreme mass spectrometer. Genomic DNA (gDNA) templates were extracted from the organisms and subjected to single nucleotide polymorphism-based multiplex polymerase chain reaction (PCR).
The team reported that the MALDI-TOF MS accurately identified all 13 P. insidiosum strains tested, at the species level. Mass spectra of P. insidiosum did not match any other microorganisms, including fungi (i.e., Aspergillus species, Fusarium species, and fungal species of the class Zygomycetes), which have similar microscopic morphologies with this oomycete. MALDI-TOF MS- and rDNA sequence-based biotyping methods consistently classified P. insidiosum into three groups: Clade-I (American strains), II (Asian and Australian strains), and III (mostly Thai strains).
The authors concluded that MALDI-TOF MS has been successfully used for identification and biotyping of P. insidiosum. The obtained mass spectral database allows clinical microbiology laboratories, well equipped with a MALDI-TOF mass spectrometer, to conveniently identify P. insidiosum, without requiring any pathogen-specific reagents (i.e., antigen, antibody or primers). The study was published in the December 2018 issue of the International Journal of Infectious Diseases.
Related Links:
Mahidol University
Latest Molecular Diagnostics News
- Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
- Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
- cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
- Rapid Point-of-Care RT-PCR Test Differentiates Influenza A/B and SARS-CoV-2 in Minutes
- Blood-Based ctDNA Test Enhances Risk Assessment in HPV-Related Throat Cancer
- WGS MCED Assay Demonstrates Rising Sensitivity and High Specificity
- ctDNA MRD Test Identifies Breast Cancer Patients Who May Avoid Surgery
- Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
- RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
- Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
- New AI Tool Improves Detection of Genetic Causes in Rare Disorders
- Adaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
- Portable Test Uses CRISPR to Rapidly Identify STIs and Resistance Markers
- New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
- First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
- Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
Lynch syndrome is a hereditary condition that increases risk for colorectal and endometrial cancers and often results in earlier-onset disease. Clinicians need better ways to stratify asymptomatic carriers... Read more
Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive condition characterized by obstructed pulmonary blood flow and strain on the right heart, with half of patients dying within five years of diagnosis.... Read more
Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
Racial survival disparities in early-stage breast cancer remain a persistent clinical concern in the United States, with Black women experiencing higher mortality despite similar treatments.... Read more
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







